Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
JAK Inhibitors in Scarring Alopecia
Description
Marianne discusses the use of Janus kinase (JAK) inhibitors in treating scarring alopecia, highlighting their role in the JAK-STAT pathway, relevant to both alopecia areata and scarring alopecia. She presents various studies showing promising results from oral JAK inhibitors like tofacitinib and brepacitinib for conditions like lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA). Notably, a recent study indicated an 85% response rate with tofacitinib in LPP, and there were positive responses reflected in reduced inflammation and improved hair regrowth. She emphasizes the efficacy of topical JAK inhibitors, especially in FFA, due to their better skin penetration and mild side effect profiles. Various trials showcased safety and mild side effects associated with these treatments. Marianne also mentions smaller studies on using oral tofacitinib in other forms of scarring alopecia, such as discoid lupus erythematosus and dissecting cellulitis, indicating potential for significant hair regrowth despite some cases yielding mixed results. The importance of continued research and patient monitoring is underscored, encouraging clinicians to report their experiences with such therapies. Overall, she posits that JAK inhibitors hold promise as therapeutic options for scarring alopecias.
View moreConclusions
- JAK inhibitors show promise as a therapeutic option for scarring alopecia, particularly lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA).
- Oral JAK inhibitors have demonstrated an average response rate of approximately 85% in treating LPP and FFA.
- Early treatment with JAK inhibitors can lead to hair follicle rescue and regrowth in cases of scarring alopecia.
- Safety profiles of JAK inhibitors are generally good, with most side effects being mild and transient.
- Topical JAK inhibitors have shown effectiveness in FFA, indicating a potentially safer administration route with lower systemic exposure.
- Delgocitinib cream has been effective in stabilizing disease in FFA patients, showing reduced clinical severity and improved inflammatory markers.
- Case reports suggest a role for JAK inhibitors in other forms of scarring alopecia, but further studies are needed to establish efficacy.
- Additional research is required to evaluate the long-term effects and safety of JAK inhibitors in various alopecia conditions.
- Nature Medicine volume 20, pages 989-990 (2014)
- [J Pathol] 2013 Oct; Vol. 231 (2), pp.236-47
- British Journal of Dermatology
- Goodarzi C., Yang C.C., et al. Tofacitinib for the treatment of lichen planopilaris: A case series. 2018.
- Alsukait R., Learned D., Rosmarin D. JDD April 2023.
- Jerjen R. et al. Folliculitis decalvans responsive to tofacitinib: A case series. Case Reports > Dermatol Ther. 2020 Nov:33(6):e13968. doi: 10.1111/dth.13968. Epub 2020 Aug 4.
- Martin A., Sharma D., Su M., Kreytak C. A Review of JAK inhibitor use in Scarring Alopecia. JAAD reviews. DOI: S2950-1989(25)00007-8.